Pravastatin Versus Simvastatin for Prevention of Contrast-Induced Nephropathy
Journal of Cardiovascular Pharmacology and Therapeutics, 08/24/2011
Clinical Article
Munoz MA et al. – Patients on pravastatin had a significantly lower incidence of contrast–induced nephropathy (CIN) compared to patients on simvastatin.
Methods- A single–center trial was to compare the incidence of CIN in patients receiving simvastatin or pravastatin therapy undergoing percutaneous coronary intervention (PCI).
- A total of 261 patients were included (145 received simvastatin and 116 received pravastatin) with the majority undergoing elective PCI.
- The population was predominantly male (65%), Hispanic (65%), and diabetic (62%), with a mean age of 59 years and a low–density lipoprotein (LDL) of 85 mg/dL.
- No significant differences were found between groups for risk factors or prophylactic strategies (eg, hydration).
- Contrast–induced nephropathy occurred in 26 patients (17.9%) in the simvastatin group versus 10 (8.6%) in the pravastatin group (P < .05).
- No patients required dialysis as a result of contrast administration.
- Acute kidney injury (AKI) occurred in 21 patients (14.5%) in the simvastatin group compared to 8 (6.9%) in the pravastatin group (P < .05).
- In multivariate analysis, the difference between statins remained an independent predictor for the development of CIN.
